-
Our Article Published in the Journal of Medicinal Chemistry
Symeres is thrilled to announce the publication of a scientific article in the prestigious Journal of Medicinal Chemistry with our colleague Koen Hekking as the main author and many more Symerians involved! We are incredibly proud of our colleagues who were instrumental in the research and development of this innovative project.
-
Peter Molenveld Assumes Role as Secretary of KNCV (Royal Netherlands Chemical Society)
Symeres is proud to announce that our colleague Dr. Peter Molenveld has been appointed as a board member of the Royal Netherlands Chemical Society (KNCV). His appointment as Secretary marks a crucial milestone in Molenveld’s career and signifies his commitment to advancing the interests of the chemical community in the Netherlands.
-
Luc van Hijfte Assumes Presidency of EFMC, Spearheading Advances in Medicinal Chemistry and Chemical Biology
Symeres is thrilled to announce that as of January 1, 2024, our sr. Vice President Dr. Luc van Hijfte has taken the helm as the President of the European Federation of Medicinal Chemistry and Chemical Biology (EFMC).
-
Interview with the Computer-Aided Drug Design (CADD) Department
Our Computer Aided Drug Design department supports our clients’ drug discovery projects with some of the best (predictive) software.
-
“If the compound can be made, Symeres will undoubtedly find out a good way to make it.” Dooyoung Jung, CEO of Pinotbio.
An in-depth interview with Doo Young Jung, the founder and CEO of our client Pinotbio in South Korea, focused on the challenge of cancer resistance/relapse
-
New scientific services from Symeres
We’re proud to announce that our brand new CMC facility at the Exemplify site of Symeres in New Jersey has been successfully completed. GMP drug product R&D facilities that will allow it to provide end-to-end services ranging from GMP and non-GMP drug product development to phase 1 and 2 clinical supplies of various oral, parenteral, and topical formulation dosage forms.
-
Interview with the new Managing Director of Symeres Groningen
On October 2, Dr Melloney Dröge started in her new role as Managing Director for the Groningen site.
-
Chiral Chemistry: in the DNA of Symeres
Over 50% of current drugs in development are chiral. At Symeres we apply a suite of state-of-the-art technologies to obtain the desired chiral compound in high enantiomeric purity. For decades, Symeres has been supporting the global pharma and biotech industry with the synthesis and delivery of chiral compounds, both through synthesis and purification strategies.
-
Interview with Richard Blaauw, Director of Operations at Organix
In April 2022, Symeres acquired Organix, a US-based CRO specializing in lipid synthesis. To aid in the incorporation of Organix into the Symeres family, and facilitate future growth transitions, Richard Blaauw has been appointed to the newly created position of Director of Operations.
-
Symeres Weert receives new GMP certificate
This week, our facility in Weert NL received a new certificate of GMP compliance from the Dutch authorities.
-
A decade of integrated drug discovery at Symeres
Symeres celebrates a decade of integrated drug discovery. Our team has been working hard to provide our clients with the best possible solutions for their needs.
-
Symeres welcomes Karen Damian to the team
We introduce you to our newest Director of Business Development. Karen Damian has a history in the drug development life sciences business.
Feel free to contact us!
Curious to know more about what can we do for you? Get in touch and let’s start a conversation.
